Basilea Pharmaceutica Aktie
| 54,40CHF | 0,00CHF | 0,00% |
WKN: A0B9GA / ISIN: CH0011432447
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 154 | 154 | 147 | 164 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,96 | 0,96 | 1,07 | 1,27 | 0,00 |
Bilanz (in Mio. CHF) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 241 | 175 | 152 | 221 | 0 |
| Summe Anlagevermögen | 6 | 45 | 21 | 37 | 0 |
| Summe Aktiva | 247 | 221 | 173 | 258 | 0 |
Bilanz (in Mio. CHF) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 306 | 242 | 183 | 177 | 0 |
| Summe Eigenkapital | -59 | -21 | -10 | 81 | 0 |
| Summe Passiva | 247 | 221 | 173 | 258 | 0 |
Adresse
| Hegenheimermattweg 167b, 4123 Allschwil | |
| Telefon | +41 (61) 606-11-11 |
| Internet | http://www.basilea.com |
Management
|
Adesh Kaul
Chief Financial Officer |
|
Alf Gunnar Martin Nicklasson
Independent Non-Executive Director |
|
Carole A. Sable
Independent Non-Executive Director |
|
Damian Heller
Secretary & General Counsel |
|
David Veitch
Chief Executive Officer |
|
Gerrit Hauck
Chief Technology Officer |
|
Laurenz Kellenberger
Chief Scientific Officer |
|
Leonard Kruimer
Independent Non-Executive Director |
|
Marc Engelhardt
Chief Medical Officer |
|
Nicole M. Onetto
Independent Non-Executive Director |
|
Peer Nils Schröder
Head-Corporate Communications & Investor Relations |
|
Stephan Schindler
Chairman |
|
Thomas Werner
Vice Chairman |
|
Ursula Eberhardt
Head-Global Human Resources |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.